Jiangsu Kanion Pharmaceutical Co Ltd (600557) — Capital Reinvestment Ratio
Jiangsu Kanion Pharmaceutical Co Ltd (600557) has a Capital Reinvestment Ratio of 0.64x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥201.83 Million) in capital expenditures (CN¥128.94 Million). See debt-free asset ratio of Jiangsu Kanion Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jiangsu Kanion Pharmaceutical Co Ltd Capital Reinvestment Ratio (2001–2024)
This chart tracks Jiangsu Kanion Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 23 annual periods. Check 600557 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Jiangsu Kanion Pharmaceutical Co Ltd (2001–2024)
Year-by-year Capital Reinvestment Ratio for Jiangsu Kanion Pharmaceutical Co Ltd from 2001 to 2024. For live market cap and broader valuation context, see Jiangsu Kanion Pharmaceutical Co Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.68x | CN¥702.49 Million | CN¥476.69 Million | ▲ +121.8% |
| 2023 | 0.31x | CN¥972.32 Million | CN¥297.48 Million | ▲ +44.4% |
| 2022 | 0.21x | CN¥995.94 Million | CN¥211.09 Million | ▲ +12.2% |
| 2021 | 0.19x | CN¥908.30 Million | CN¥171.52 Million | ▼ -30.4% |
| 2020 | 0.27x | CN¥701.10 Million | CN¥190.32 Million | ▼ -48.7% |
| 2019 | 0.53x | CN¥925.73 Million | CN¥490.06 Million | ▲ +6.7% |
| 2018 | 0.50x | CN¥636.39 Million | CN¥315.73 Million | ▼ -27.2% |
| 2017 | 0.68x | CN¥382.93 Million | CN¥260.94 Million | ▼ -37.4% |
| 2016 | 1.09x | CN¥299.02 Million | CN¥325.24 Million | ▲ +49.4% |
| 2015 | 0.73x | CN¥514.80 Million | CN¥374.80 Million | ▼ -26.7% |
| 2014 | 0.99x | CN¥311.54 Million | CN¥309.36 Million | ▲ +13.6% |
| 2013 | 0.87x | CN¥388.11 Million | CN¥339.23 Million | ▼ -27.0% |
| 2012 | 1.20x | CN¥212.11 Million | CN¥253.88 Million | ▼ -63.2% |
| 2011 | 3.25x | CN¥90.19 Million | CN¥293.53 Million | ▲ +90.1% |
| 2010 | 1.71x | CN¥166.40 Million | CN¥284.89 Million | ▲ +15.3% |
| 2008 | 1.48x | CN¥58.39 Million | CN¥86.69 Million | ▲ +133.8% |
| 2007 | 0.63x | CN¥92.73 Million | CN¥58.88 Million | ▲ +182.2% |
| 2006 | 0.22x | CN¥108.98 Million | CN¥24.52 Million | ▼ -57.3% |
| 2005 | 0.53x | CN¥101.44 Million | CN¥53.39 Million | ▼ -90.7% |
| 2004 | 5.66x | CN¥21.68 Million | CN¥122.68 Million | ▼ -23.5% |
| 2003 | 7.40x | CN¥17.13 Million | CN¥126.72 Million | ▼ -6.3% |
| 2002 | 7.90x | CN¥11.15 Million | CN¥88.07 Million | ▲ +800.5% |
| 2001 | 0.88x | CN¥21.02 Million | CN¥18.43 Million | — |